Synthesis and biological evaluation of aryl incorporated (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)oxazolo[5,4-b]pyridine derivatives as anticancer agents

IF 2.4 Q2 Chemistry

Chemical Data Collections Pub Date : 2026-02-01 Epub Date: 2025-12-14 DOI:10.1016/j.cdc.2025.101219

Palreddy Reshma , Saikrishna Balabadra , Swapna Maarepalli

{"title":"Synthesis and biological evaluation of aryl incorporated (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)oxazolo[5,4-b]pyridine derivatives as anticancer agents","authors":"Palreddy Reshma , Saikrishna Balabadra , Swapna Maarepalli","doi":"10.1016/j.cdc.2025.101219","DOIUrl":null,"url":null,"abstract":"<div><div>A new library of aryl incorporated (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)oxazolo[5,4-b]pyridine (<strong>9a-j</strong>) compounds are developed to explore new heterocyclic scaffolds with potential anticancer properties. The structural novelty of these hybrids arises from the strategic combination of an oxazolo[5,4-b]pyridine core with a 1,3,4-oxadiazole linker and diverse aryl moieties—an arrangement not previously investigated for anticancer applications. All synthesized compounds were thoroughly characterized by analytical and spectroscopic techniques. Further, the anticancer activity of the newly prepared compounds (<strong>9a-j</strong>) was assessed against a panel of four human cancer cell lines like human breast cancer (MCF-7), human lung cancer (A549), human colon cancer (Colo-205) & human ovarian cancer (A2780) by using of the MTT assay, and the results are compared with the known chemotherapeutic agent etoposide. All the investigated derivatives displayed moderate to good activity. Notably, compounds 9a, 9 g, 9 h, 9i, and 9j showed the most promising results, with compound 9j demonstrating exceptional potency across the tested models.</div></div>","PeriodicalId":269,"journal":{"name":"Chemical Data Collections","volume":"61 ","pages":"Article 101219"},"PeriodicalIF":2.4000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Data Collections","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405830025000412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Chemistry","Score":null,"Total":0}

引用次数: 0

Abstract

A new library of aryl incorporated (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)oxazolo[5,4-b]pyridine (9a-j) compounds are developed to explore new heterocyclic scaffolds with potential anticancer properties. The structural novelty of these hybrids arises from the strategic combination of an oxazolo[5,4-b]pyridine core with a 1,3,4-oxadiazole linker and diverse aryl moieties—an arrangement not previously investigated for anticancer applications. All synthesized compounds were thoroughly characterized by analytical and spectroscopic techniques. Further, the anticancer activity of the newly prepared compounds (9a-j) was assessed against a panel of four human cancer cell lines like human breast cancer (MCF-7), human lung cancer (A549), human colon cancer (Colo-205) & human ovarian cancer (A2780) by using of the MTT assay, and the results are compared with the known chemotherapeutic agent etoposide. All the investigated derivatives displayed moderate to good activity. Notably, compounds 9a, 9 g, 9 h, 9i, and 9j showed the most promising results, with compound 9j demonstrating exceptional potency across the tested models.

Abstract Image

查看原文本刊更多论文

芳基结合（吡啶-4-基）-1,3,4-恶二唑-2-基)恶唑[5,4-b]吡啶衍生物抗癌剂的合成及生物学评价

为了探索新的具有潜在抗癌特性的杂环支架，建立了一个新的芳基结合（吡啶-4-基）-1,3,4-恶二唑-2-基)恶唑[5,4-b]吡啶（9a-j）化合物文库。这些杂合体的结构新颖源于恶唑[5,4-b]吡啶核心与1,3,4-恶二唑连接体和多种芳基基团的战略性组合，这种排列以前未被研究用于抗癌应用。所有合成的化合物都通过分析和光谱技术进行了彻底的表征。此外，采用MTT法对新制备的化合物（9a-j）对人乳腺癌（MCF-7）、人肺癌（A549）、人结肠癌（Colo-205）和人卵巢癌（A2780） 4种人类癌细胞系的抗癌活性进行了评价，并与已知的化疗药物依托opo苷进行了比较。所研究的衍生物均表现出中等至良好的活性。值得注意的是，化合物9a、9g、9h、9i和9j显示出最有希望的结果，其中化合物9j在所有测试模型中都表现出优异的效力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemical Data Collections Chemistry-Chemistry (all)

CiteScore

6.10

自引率

0.00%

发文量

169

审稿时长

24 days

期刊介绍： Chemical Data Collections (CDC) provides a publication outlet for the increasing need to make research material and data easy to share and re-use. Publication of research data with CDC will allow scientists to: -Make their data easy to find and access -Benefit from the fast publication process -Contribute to proper data citation and attribution -Publish their intermediate and null/negative results -Receive recognition for the work that does not fit traditional article format. The research data will be published as ''data articles'' that support fast and easy submission and quick peer-review processes. Data articles introduced by CDC are short self-contained publications about research materials and data. They must provide the scientific context of the described work and contain the following elements: a title, list of authors (plus affiliations), abstract, keywords, graphical abstract, metadata table, main text and at least three references. The journal welcomes submissions focusing on (but not limited to) the following categories of research output: spectral data, syntheses, crystallographic data, computational simulations, molecular dynamics and models, physicochemical data, etc.